Harald Zeuner

481 total citations
11 papers, 143 citations indexed

About

Harald Zeuner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Harald Zeuner has authored 11 papers receiving a total of 143 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Harald Zeuner's work include Lung Cancer Treatments and Mutations (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Lung Cancer Research Studies (3 papers). Harald Zeuner is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Lung Cancer Research Studies (3 papers). Harald Zeuner collaborates with scholars based in Switzerland, Germany and Italy. Harald Zeuner's co-authors include Robert Marcus, Wolfgang Hiddemann, Deniz Şahin, Tina Nielsen, Andrea Knapp, Marek Trněný, Andrés F. Cardona, Mikkel Z. Oestergaard, Walter Bordogna and Jeffrey M. Venstrom and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Harald Zeuner

11 papers receiving 143 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harald Zeuner Switzerland 6 99 62 52 35 23 11 143
Allison Barraclough Australia 8 87 0.9× 106 1.7× 20 0.4× 21 0.6× 30 1.3× 29 152
Muhammed B. Sabdia Australia 6 96 1.0× 66 1.1× 55 1.1× 8 0.2× 11 0.5× 17 144
Laëtitia Nebot-Bral France 5 115 1.2× 64 1.0× 28 0.5× 49 1.4× 7 0.3× 6 166
David Šálek Czechia 8 102 1.0× 130 2.1× 18 0.3× 27 0.8× 44 1.9× 23 156
Olaf Determann Germany 4 130 1.3× 195 3.1× 24 0.5× 56 1.6× 82 3.6× 4 214
Von Potter United States 5 120 1.2× 37 0.6× 32 0.6× 37 1.1× 53 2.3× 8 154
Kristin Stirm Switzerland 5 62 0.6× 48 0.8× 60 1.2× 12 0.3× 30 1.3× 7 124
Farheen Mir United Kingdom 6 74 0.7× 109 1.8× 14 0.3× 18 0.5× 25 1.1× 13 167
Silja Mack Germany 4 63 0.6× 52 0.8× 49 0.9× 22 0.6× 89 3.9× 6 265
A. Rosenwald Germany 5 85 0.9× 81 1.3× 50 1.0× 14 0.4× 21 0.9× 10 173

Countries citing papers authored by Harald Zeuner

Since Specialization
Citations

This map shows the geographic impact of Harald Zeuner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harald Zeuner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harald Zeuner more than expected).

Fields of papers citing papers by Harald Zeuner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harald Zeuner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harald Zeuner. The network helps show where Harald Zeuner may publish in the future.

Co-authorship network of co-authors of Harald Zeuner

This figure shows the co-authorship network connecting the top 25 collaborators of Harald Zeuner. A scholar is included among the top collaborators of Harald Zeuner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harald Zeuner. Harald Zeuner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Fan, Yun, Alexander Drilon, Chao‐Hua Chiu, et al.. (2023). Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 25(2). e81–e86.e4. 1 indexed citations
2.
Cho, Byoung Chul, Chao‐Hua Chiu, Erminia Massarelli, et al.. (2023). Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. Lung Cancer. 188. 107442–107442. 19 indexed citations
3.
Lü, Shun, Filippo de Braud, Yun Fan, et al.. (2023). 666P Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours. Annals of Oncology. 34. S468–S469. 2 indexed citations
4.
Cho, Byoung Chul, Chao‐Hua Chiu, Erminia Massarelli, et al.. (2023). Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). 9047–9047. 2 indexed citations
5.
Krzakowski, Maciej, Shun Lü, Sophie Cousin, et al.. (2022). Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3099–3099. 23 indexed citations
6.
Klánová, Magdalena, Mikkel Z. Oestergaard, Marek Trněný, et al.. (2019). Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. Clinical Cancer Research. 25(15). 4634–4643. 54 indexed citations
7.
Bendell, J. C., Christopher H. Lieu, Kanwal Raghav, et al.. (2019). A phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC). Annals of Oncology. 30. v227–v228. 3 indexed citations
8.
9.
10.
Herold, Michael, Eva Hoster, Ann Janssens, et al.. (2017). IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL). Hematological Oncology. 35(S2). 146–147. 13 indexed citations
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Allison Barraclough Breakdown of academic impact, for papers by Muhammed B. Sabdia Breakdown of academic impact, for papers by Laëtitia Nebot-Bral Breakdown of academic impact, for papers by David Šálek Breakdown of academic impact, for papers by Olaf Determann Breakdown of academic impact, for papers by Von Potter Breakdown of academic impact, for papers by Kristin Stirm Breakdown of academic impact, for papers by Farheen Mir Breakdown of academic impact, for papers by Silja Mack Breakdown of academic impact, for papers by A. Rosenwald
Rankless by CCL
2026